Philip J. Mease, MD, from Swedish Medical Center, discusses results from a phase 2 clinical trial on tildrakizumab—an anti-interleukin-23p19 monoclonal antibody—and its potential as a therapeutic option for psoriatic arthritis. The research was presented during the late-breaking session at the Annual European Congress of Rheumatology.
Philip J. Mease, MD, is director of rheumatology research at Swedish Medical Center in Seattle, Washington, and a clinical professor at the University of Washington School of Medicine in Seattle, Washington.
For more EULAR content, visit the Resource Center.
Reference:
Mease PJ, Chohan S, García Fructuoso FJ, et al. Randomised, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti-interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis [EULAR abstract LB0002]. Ann Rheum Dis. 2019;78(suppl 2):A78. http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=Tildrakizumab&view=1&item=2019LB0002. Accessed August 22, 2019.
Financial Disclosures: Dr Mease has served as a paid consultant to AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos NV, Gilead Sciences, Janssen Pharmaceuticals, Eli Lilly and Company, Novartis, Pfizer, Sun Pharmaceutical Industries, and UCB. Dr Mease has served as a speaker to AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen Pharmaceuticals, Eli Lilly and Company, Novartis, Pfizer, and UCB. Dr Mease has received research grants from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Eli Lilly and Company, Novartis, Pfizer, Sun Pharmaceutical Industries, and UCB.
